Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer.

Abstract

EGF receptor (EGFR) targeting in patients with wild-type KRAS metastatic colorectal cancer has been associated with clinical activity in first-, second- and third-line therapies. Panitumumab, a human monoclonal antibody that targets EGFRs, had previously been associated with tumor regressions and improved progression-free survival in patients with… (More)
DOI: 10.2217/fon.10.181

Topics

  • Presentations referencing similar topics